We evaluated the expression of COX2 in the yet largest cohort of 1048 vestibular schwannomas including 115 schwannomas of NF2 patients and compared the expression with demographic factors as well as tumor extension, MIB1 expression and the intake of COX2 responsive medication. This evidence concerns the gene PTGS2 and schwannoma.